glp-1 grey market Drugs Size to Hit USD 132.79 Bn by 2035 The Multi-Sector Impacts of GLP-1RA

Here's the latest news on that story.

Among Medicare patients, 18% started with a GLP-1 while 24% used an SGLT2, reflecting the higher prevalence of cardiovascular conditions in seniors and the dual benefits SGLT2s provide in heart health

Awareness of the latest AOM molecules and brands is lowest among GPs/IMs IQVIAs primary research was conducted shortly after the 3rd October announcement of the NHS England/Lilly deal for the phased launch of Mounjaro for obesity

Such programs might include traditional copay cards and vouchers, but more frequently brands are launching with generous bridge and denial conversion programs that facilitate patient access by offsetting most of the drug cost in lieu of payer coverage